Skip to main
RMD

ResMed (RMD) Stock Forecast & Price Target

ResMed (RMD) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

ResMed is a fundamentally strong company with a positive outlook due to its strong financial performance, including revenue growth and gross margin expansion, and its investments in digital health technology to differentiate itself from competitors. However, potential concerns about competition in international markets and continued high opex levels may give some investors pause. The company's recent earnings beat and increasing guidance for FY26 are positive indicators, but the potential impact of GLP-1 drugs on PAP volumes could be a medium-term disruption.

Bears say

ResMed is facing several risks and challenges that could negatively impact its stock, including potential disruptions in its key revenue driver, CPAP technology, from the emergence of GLP-1 therapeutics. Additionally, despite recent acquisitions and a focus on digital health, competition and market saturation may limit the company's ability to gain market share. However, there may be potential upside from the growing market for sleep apnea and other chronic diseases, as well as positive surprises from new technology and market opportunities. Investors should keep an eye on utilization rates for CPAP technology and the company's ability to differentiate itself in a competitive landscape.

ResMed (RMD) has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ResMed (RMD) Forecast

Analysts have given ResMed (RMD) a Buy based on their latest research and market trends.

According to 10 analysts, ResMed (RMD) has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $292.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $292.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ResMed (RMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.